, Volume 97, Issue 2, pp 291-293

Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by thrombocytopenia secondary to accelerated platelet destruction and suboptimal platelet production [1]. The standard first-line treatment for adults with ITP who are symptomatic or have a significant risk of bleeding consists of corticosteroids. Most patients who are unresponsive to treatment with corticosteroids or intravenous immunoglobulins require second-line therapies, either splenectomy or pharmaceutical therapies such as azathioprine, danazol, or rituximab [2]. Two thrombopoietin receptor (TPO-R) agonists, romiplostim and eltrombopag have recently been licensed for use in patients with refractory ITP [35]. We herein report the case of a patient with ITP refractory to other therapies, including eltrombopag, which was successfully managed with romiplostim.

A 63-year-old female was diagnosed with ITP at another hospital in March 2010. Her platelet count was 3 × 109/L at diagnosis. She was initially